5 High Growth Healthcare Stocks to Buy Now

Page 1 of 5

In this article, we will list the 5 High Growth Healthcare Stocks to Buy Now. Please visit 11 High Growth Healthcare Stocks to Buy Now if you would like to see the extended list and the methodology behind it.

11 High Growth Healthcare Stocks to Buy Now

5. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the best high growth healthcare stocks to buy now. Cantor Fitzgerald cut the price target on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to $31 from $35 on March 13, reiterating an Overweight rating on the shares and telling investors in a research note that it updated its model after the fiscal Q4 earnings report, which includes pruning estimates for both Syfovre and Empaveli.

In its fiscal Q4 and full year 2025 financial results, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) reported net product revenues of $689 million for the full year 2025, with SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 million and EMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 million. It also stated that the regulatory submission for SYFOVRE prefilled syringe is planned for the first half of 2026. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has cash and cash equivalents of $466 million as of December 31, 2025, with projected revenues, cash, and cash equivalents anticipated to be sufficient to fund operations to profitability.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes novel therapeutic compounds for treating diseases with unmet needs. Its product portfolio primarily includes EMPAVELI and SYFOVRE. SYFOVRE treats geographic atrophy secondary to age-related macular degeneration (GA), while EMPAVELI treats paroxysmal nocturnal hemoglobinuria (PNH).

Page 1 of 5